Skip to main content

Diagnostic yield and incremental case detection of Urine LF-LAM among adults and children with advanced HIV disease in Nigeria: a prospective programmatic evaluation

In brief

Urine TB testing adds 941 positive results beyond sputum testing in advanced HIV

In routine care across 334 Nigerian facilities, urine LF-LAM was positive in 30.4% of 17,155 adults and children with advanced HIV disease. Among participants with paired results, it identified 941 people whose GeneXpert test was negative; many positive participants lacked typical symptoms or could not provide sputum. The added detection is important, but paired results were available for fewer than half the cohort.

Journal
Journal of clinical tuberculosis and other mycobacterial diseases (Q2)
Published
7 November 2026
Study design
Prospective / inception cohort
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Justin Onyebuchi Nwofe, Laura Ifunanya Madukaji, Daniel Chinenyeike Offie, Dickson Adeolu Adetoye, Emmanuel Adewale Ojo, Magnus Odido, et al.
PMID
43061250
DOI
10.1016/j.jctube.2026.100650

Why clinicians should know about it

  • Picked for Microbiology (medical) (top studies of the week, 22 November 2026): Large programmatic evaluation of urine LF-LAM TB diagnostic yield

Abstract

Diagnosing tuberculosis (TB) in people with advanced HIV disease (AHD) remains challenging, particularly in the absence of typical symptoms or obtainable sputum. We evaluated the diagnostic yield and incremental case detection of urine lateral-flow lipoarabinomannan (LF-LAM) testing within routine AHD care in Nigeria. This prospective programmatic evaluation included adults and children with AHD across 334 HIV treatment facilities between July 2022 and July 2025. Participants underwent Determine TB-LAM Ag testing at presentation, with sputum GeneXpert MTB/RIF performed according to the programme diagnostic algorithm. Of 17,155 participants tested, 5212 were LF-LAM positive, yielding an overall diagnostic yield of 30.4% (95% CI 29.7-31.1%). Among these, 2074 (39.8%) had no WHO-defined presumptive TB symptoms, while 283 presumptive TB participants who were unable to produce sputum tested LF-LAM positive. Among 7603 participants with paired LF-LAM and GeneXpert results, 4323 were positive by at least one assay, including 941 LF-LAM-positive/GeneXpert-negative participants, representing an incremental detection proportion of 21.8% (95% CI 20.6-23.0%). Across the entire cohort, 6680 participants tested positive by either assay. Urine LF-LAM complemented sputum GeneXpert by identifying additional test-positive participants particularly among individuals without presumptive symptoms or obtainable sputum. Integrating LF-LAM into routine AHD care may help close important diagnostic gaps in high TB/HIV-burden settings.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.